BioCentury | Aug 9, 2017
Distillery Therapeutics

Neurology

INDICATION: Insomnia Mouse studies suggest inhibiting ARNTL could help treat tuberous sclerosis complex (TSC)-associated sleep disorder. In cortical tissue samples from a mouse model of TSC, levels of ARNTL were higher and varied less with...
BioCentury | Jul 10, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A 10-gene signature in tumors could help predict survival in breast cancer. In 4,994 breast cancer patients, low tumors levels of a signature based on the expression of 10 genes -- including...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Patient sample, cell culture and mouse studies suggest promoting ARNTL expression could help treat tongue squamous cell carcinoma. In patient tumor samples or three human tongue squamous cell carcinoma cell...
BioCentury | Apr 21, 2016
Distillery Therapeutics

Therapeutics: Aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2; BMAL2)

...and mouse studies suggest inhibiting ARNTL2 could help treat metastatic lung adenocarcinoma. In patient samples, ARNTL2...
...progression and poor survival. In multiple mouse and human lung adenocarcinoma cell lines, shRNA targeting ARNTL2...
...include identifying and testing ARNTL2 inhibitors to help treat metastatic lung adenocarcinoma. TARGET/MARKER/PATHWAY: Aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2; BMAL2...
BioCentury | Jun 4, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-155 (miR-155); aryl hydrocarbon receptor nuclear translocator-like (ARNTL; BMAL1)

Inflammation INDICATION: Inflammation In vitro and mouse studies suggest inhibiting miR-155 could help reduce inflammation in sepsis. In mouse models of sepsis, zeitgeber time 12 (ZT12) - the transition to the active phase of the day...
Items per page:
1 - 5 of 5